Boehringer Ingelheim reaches more patients in 2024 and prepares new medicine launches - Middle East Business News and Information
In 2024, Boehringer Ingelheim in India, Middle East, Turkey and Africa (IMETA) region achieved net sales of EUR 855 million, reflecting a 17% increase compared to the previous year.
R&D investments rise to EUR 6.2 billion, 23.2% of group net sales.
Company prepares new product launches starting in 2025.
Dubai, United Arab Emirates: Boehringer Ingelheim today announced a continued rise in the number of patients it reached, 66 million in 2024, up 8.0% from the previous year. Development of its current product pipeline is well on track, as the company prepares multiple new product launches, starting in 2025. Research & Development (R&D) investments rose to EUR 6.2 billion, or 23.2% of group net sales. Group net sales rose by 6.1%* to EUR 26.8 billion.
'As our current pipeline continues to mature and more products come closer to a potential market introduction, we have entered a pivotal phase of high investments, to bring these new innovations to patients,' said Hubertus von Baumbach, Chairman of the Board of Managing Directors. 'It is important that we use every opportunity to bring these new treatments to patients as fast as possible – this is our number one priority.'
Strong Growth in IMETA:
In India, Middle East, Turkey, and Africa (IMETA) region, the company recorded net sales of 855 million EUR (2023: 732 million EUR), a 17% increase compared to the previous year.
Derek O'Leary, Regional Managing Director at Boehringer Ingelheim India, Middle East, Turkey and Africa (IMETA) said: 'Our strong performance in 2024 underscores our commitment to addressing unmet medical needs in both human and animal health. We will continue to work towards expanding access to innovative treatments for people and strengthen our efforts to safeguard animal health and well-being, impacting a greater number of lives. In partnerhip with our stakeholders, we are eager to build on this momentum in 2025 through further science-backed innovations tailored to the needs of both patients and animals.'
Human Pharma: investing in existing products and new launches
Human Pharma sales rose by 7.0%* to EUR 21.9 billion, led by the treatment of chronic kidney diseases, type 2 diabetes and heart failure, rose 14.6%* to EUR 8.4 billion. Treatments used for idiopathic pulmonary fibrosis and certain fibrosing interstitial lung diseases, grew 8.9%* to EUR 3.8 billion.
The Human Pharma pipeline includes over ten new Phase II and III trials over the next 12 to 18 months, which will potentially result in a range of significant launches in the next five years. Human Pharma R&D spending rose to EUR 5.7 billion, or 27.6% of the business unit's net sales.
'If we look at the past five years, Boehringer Ingelheim has invested approximately EUR 25 billion in R&D,' said Frank Hübler, Member of the Board of Managing Directors with responsibility for Finance. 'With the innovations currently in our pipeline we will further increase investments in R&D in the years to come.'
After positive data from pivotal studies, the company is preparing multiple new product launches to advance care for patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis as well as the first orally administered, targeted therapy for previously treated HER2-mutated lung cancer patients.
Both treatments have been submitted to regulatory authorities globally and first launches in the US are anticipated in the second half of this year, pending approval.
Animal Health: rapid response against transboundary animal diseases
Animal Health sales rose 1.9%* to EUR 4.7 billion in 2024, mainly driven by Pet Parasiticides and Therapeutics, Poultry and Ruminant. The parasiticides continued to strengthen its position as the top-selling brand in the industry, growing 14.0%* to EUR 1.4 billion.
Last year, Boehringer Ingelheim supported livestock producers and governments by quickly providing vaccines and technical assistance for outbreaks of transboundary animal diseases (TADs), such as avian influenza, bluetongue virus and foot-and-mouth disease. These diseases pose a significant risk to animal health, impede global trade, and constrain food supply.
Sustainable Development:
Boehringer Ingelheim is on track in its target to become carbon neutral in its company operations by 2030. It increased global renewable electricity purchases to around 75% in 2024, primarily due to transitioning to renewable solutions at various sites, including Japan and China. A new biomass power plant was also commissioned at its Ingelheim site in Germany to boost on-site renewable energy generation to 95% of its energy needs.
As part of its global effort to stop rabies, the company provided 46 million rabies vaccine doses and supported vaccination campaigns in endemic countries. The 'Angels' initiative, which aims to optimize the quality of treatment in existing stroke centers, added over 1,000 organizations to the network. It is the largest stroke community in the world, now encompassing 237,000 healthcare professionals from more than 9,000 hospitals in 158 countries and has helped 19 million stroke patients to date.
Outlook:
The general trends and developments of the past year are expected to continue to impact 2025. The company expects a continued rise in the number of patients reached, and a slight year-on-year increase in net sales, adjusted for currency and extraordinary effects.
* sales growth numbers are adjusted for currency effects
**one-sided p-value from a z-test of the null hypothesis ORR ≤30%
Boehringer Ingelheim:
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mid East Info
2 hours ago
- Mid East Info
Tuum Selected by Uptex Bank to Power E-Banking Expansion in Middle East and Africa - Middle East Business News and Information
Dubai, UAE – August 13, 2025 – Tuum, the leading next-generation core banking provider, has been selected by Oliver Business Development (OBD) Holding to power its newly licensed e-banking services in the Middle East and Africa (MEA) called Uptex Bank. The partnership marks Tuum's first customer in the Middle East and reinforces its strategy to support innovation-led financial institutions in fast-growing, regulated markets. Following the recent acquisition of its e-banking license, OBD is launching Uptex Bank, a suite of digital wallet and payment services designed to unify its growing financial ecosystem. This includes Uptex Broker, a forex and CFD broker in MEA, and Rizzbees, its EU-licensed Crypto Exchange Platform. The new proposition will run on Tuum's modular, cloud-native core, deployed via AWS in Europe and purpose-built for scalability, compliance, and rapid go-to-market. Uptex Bank was looking for a partner who could help them deliver a Minimum Viable Product (MVP) in a very short timeframe without compromising on scale or regulatory readiness. Tuum's approach as a true partner, rather than a vendor, was key to making this possible. 'We're building a unique e-money proposition that brings together traditional and next-gen financial services into one seamless ecosystem,' said Archie Sol, Chief Marketing Officer. ' Tuum stood out as the platform to help us achieve this vision. From their sleek technology to the responsiveness of their team, it was clear that they're not just a vendor—they're a partner. With Tuum, we're not only launching fast, we're building for scale. Uptex Bank is built for people tired of the old way banks treat them. From Gen Z and digital-first users to everyday customers seeking something faster, fairer, and more intuitive. With Tuum's flexible, API-first platform, we're creating a banking experience that's modern, human, and built for how people live now, not how banks used to operate.' Crucially, Tuum's API-first infrastructure allows Uptex Bank to seamlessly integrate its new e-banking services with its existing brokerage and crypto exchange, enabling a unified, interoperable financial environment across its brands. The solution is fully aligned with Oman's regulatory framework, including requirements from the Central Bank of Oman and the Capital Market Authority. Tuum's technology will also enable OBD to support digital wallets and multi-currency payments (USD, EUR, GBP, AED, OMR, SAR) from day one. The group expects to onboard more than 50,000 users in its first year, with millions of transactions anticipated across its fintech portfolio. Uptex Bank selected Tuum through a competitive process, with speed, scalability, and regulatory readiness emerging as key differentiators. With an MVP launch planned within months, Tuum's ability to move fast while delivering enterprise-grade control gave Uptex Bank the confidence to move forward. Beyond the core platform, Tuum also worked closely with Uptex Bank to bring together the right ecosystem partners for the initiative ensuring each aligned with Uptex Bank's specific use cases and business model. 'This is a landmark win for Tuum,' said Miljan Stamenkovic, Chief Revenue Officer at Tuum. ' It shows the rising demand for modern, modular core banking platforms in the Middle East. OBD is building an ambitious and truly differentiated proposition in Oman and we're proud to provide the infrastructure behind it.' -Ends-
Mid East Info
2 days ago
- Mid East Info
COT Report: Speculators slash commodity longs to 11-month low, gold remains dominant
Ole Hansen, Head of Commodity Strategy, Saxo Bank Commodities In the week to August 5, several major developments drove positioning changes across key commodities. Trump's abrupt reversal on copper tariffs triggered a 22% slump in New York prices, prompting funds to halve their HG copper net long. In energy, OPEC+'s continued production increases—potentially into a softening demand period—pressured crude oil, while fading tightness in the diesel market led to long liquidation in London and New York from recent three-year highs. Grains remained under pressure as favourable U.S., European, and Black Sea weather maintained strong crop prospects, reinforcing elevated speculative short positions across wheat, corn, and soybeans. Notably, soybean futures jumped 2.5% in early Monday trade after Trump urged China to quadruple U.S. soy purchases as part of efforts to cut its trade deficit with China. As of late July, US government data showed China, the world's top buyer of soybeans, had yet to book any cargoes for the upcoming season that starts in September as tensions between the two sides linger. Overall, managed money accounts engaged in broad-based selling, with most of the 27 major commodity futures tracked seeing net reductions. The combined net long fell to an 11-month low of 540,000 contracts, valued at USD 107 billion. More than half of this nominal value came from gold's 161,811-contract net long—which, in contrast to the broader trend, rose 13% last week as a weaker-than-expected U.S. jobs report and potential dovish shift from the FOMC boosted September rate-cut expectations. Forex Despite emerging signs of the recent dollar recovery had run out of steam, speculators extended their recent buying spree to six leading to a considerable amount of further dollar short-covering. Overall, the gross USD short versus eight IMM forex futures slumped by 38% to USD 7.1 billion, the lowest belief in a weaker dollar since April, with selling seen across all eight except the Mexican peso, and led by JPY, EUR and not least GBP after the net short jumped to near a three-year high. Another extreme emerged in AUD where the net short reached an 18-month high.
Mid East Info
6 days ago
- Mid East Info
BoE cuts rates to 4% but decision was less clear than expected - Middle East Business News and Information
By Daniela Sabin Hathorn, senior market analyst at The Bank of England BoE delivered its fifth rate cut in a year on Thursday, lowering the Bank Rate by 25 basis points to 4.00%. The decision reflects mounting concerns over the UK's weakening economic momentum, even as inflation remains stubbornly above target. The Monetary Policy Committee MPC vote revealed a rare and significant 5–4 split, with notable disagreement among members about the size and timing of the rate cut. One member reportedly advocated for a 50 basis point cut, prompting a second round of voting—an uncommon move that underscores the current uncertainty within the Committee. The vote split was expected to come in at 8-1. The fact that four MPC members voted to keep the rate unchanged was a lot less dovish than anticipated, prompting the pound to rise on the back of it. GBP/USD and GBP/JPY are both up 0.45% since the announcement, whilst EUR/GBP is down 0.5%. The decision to ease monetary policy further comes in response to a cooling UK economy. Recent data shows GDP has contracted over recent months, alongside rising unemployment, as labour market conditions soften. However, with inflation still above 3%, the risk of stagflation is becoming more apparent, with several policymakers showing this concern by opting to vote to keep rates unchanged. In its accompanying statement, the Bank reiterated its intention to proceed with 'a gradual and careful' easing path. Further cuts are expected to be modest, and only if economic data justifies continued loosening. Markets interpreted this as a dovish hold on future actions, with the Bank opting to retain flexibility amid competing risks. Updated Economic Projections: Growth Forecasts: GDP is now projected to expand 1.25% in 2025 and in 2026. Inflation Outlook: Price growth is not expected to return to the 2% target until early 2027, reflecting persistent structural inflationary pressures. Policy Path: the BoE's non-committal and data dependant approach has led markets to remove some of the further easing priced in for the end of 2025, with just 15bps of easing as of now.
